Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x100px

Product › Details

BiTE™ molecule (Micromet)

	Next higher product group	pharmaceutical active protein
	Status	2003-06-26 development existent
	Organisation	Micromet AG
	Today	Amgen Research (Munich) GmbH
	Group	Amgen (Group)

Record changed: 2023-07-10

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for pharmaceutical active protein

[1] AATec Medical GmbH. (10/31/23). "Press Release: AATec Medical and Beurer Enter Development Collaboration for Inhaled Alpha-1 Antitrypsin". Munich....
[2] Navigo Proteins GmbH. (9/6/23). "Press Release: Navigo Proteins and Nostrum Biodiscovery Announce a Research Collaboration to Enhance Affilin Ligand Discovery Using Cutting-edge AI and Molecular Modeling Techniques". Halle (Saale) & Barcelona....
[3] Pieris Pharmaceuticals, Inc.. (8/17/23). "Press Release: Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific". Boston, MA....
[4] Pieris Pharmaceuticals, Inc.. (7/18/23). "Press Release: Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring". Boston, MA....
[5] AATec Medical GmbH. (7/17/23). "Press Release: AATec Medical Announces Its Launch with EUR 2.7 Million in Seed Financing to Unlock the Therapeutic Potential of Alpha-1 Antitrypsin". Munich....
[6] Abionyx Pharma S.A.. (7/13/23). "Press Release: Abionyx Pharma Announces the Appointment of Laurent Guerci as Chief Digital & Innovation Officer". Toulouse & Lakeland, MI....
[7] Mallia Therapeutics GmbH. (7/11/23). "Press Release: Mallia Therapeutics Secures Seed Funding for its Novel Topical Treatment to Induce Hair Growth via Immune Modulation". Erlangen....
[8] Pieris Pharmaceuticals, Inc.. (6/21/23). "Press Release: Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study". Boston, MA....
[9] Amgen Inc.. (12/13/22). "Press Release: Blincyto (blinatumomab) Added to Consolidation Chemotherapy Significantly Improves Survival in Adult Patients with Measurable Residual Disease-negative B-Lieage Acute Lymphoblastic Leukemia (B-ALL)". Thousand Oaks,...
[10] Synerkine Pharma B.V.. (12/16/21). "Press Release: Synerkine Pharma Raises EUR 3.5 Million in an Extended Series A Financing". Naarden....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]